Analysts: this year best year ever for Carl Zeiss Meditec

Tomorrow the German Carl Zeiss Meditec will publish its past quarter figures. For this year Carl Zeiss Meditec 's revenue will be around 2.23 billion euros. This is according to the average of the analysts' estimates. The expected revenue would be a record for the company. This is slightly more than 2022's revenue of 2.09 billion euros.

Historical revenues and results Carl Zeiss Meditec plus estimates 2023

Carl Zeiss Meditec Zeiss Duisburg © Carl Zeiss Meditec

The analysts expect for 2023 a net profit of 248 million euros. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 2.8 euros. So the price/earnings-ratio equals 37.84.

Per share the analysts expect a dividend of 1.05 euros per share. The dividend yield is then 0.99 percent. The average dividend yield of the pharmaceutical companies is an attractive 2.07 percent.

Newest target prices around 94 euros

The most recent recommendations for the pharmaceutical company are from UBS , Stifel and JP Morgan.

Carl Zeiss Meditec 's market capitalization is based on the number of outstanding shares around 9.48 billion euros.

At 17.36 the stock trades 1.34 percent higher at 105.95 euros.

Historical stock prices Carl Zeiss Meditec

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.